Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels

Journal of Viral Hepatitis

Volumn 22, Issue 12, 2015, Pages 977-982

  Younossi, Z M ^a,b   Elsheikh, E ^a,b   Stepanova, M ^b   Gerber, L ^b   Nader, F ^a,b   Stamm, L M ^c   Brainard, D M ^c   McHutchinson, J G ^c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b Betty and Guy Beatty Center for Integrated Research   (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

apoE; apolipoprotein; hepatitis C virus; ledipasvir; ribavirin; sofosbuvir

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ASPARTATE AMINOTRANSFERASE; LEDIPASVIR PLUS SOFOSBUVIR; ANTIVIRUS AGENT; APOLIPOPROTEIN; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; RIBAVIRIN; SOFOSBUVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; VIRAL CLEARANCE; VIRUS INFECTIVITY; VIRUS LOAD; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; MIDDLE AGED; VIROLOGY;

ANTIVIRAL AGENTS; APOLIPOPROTEINS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RIBAVIRIN; SOFOSBUVIR;

EID: 84945436502     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12448     Document Type: Article

References (24)

1. Lavanchy D,. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17 (2): 107-115.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49 (4): 1335-1374.
3. Meunier JC, Engle RE, Faulk K, et al,. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci USA 2005; 102 (12): 4560-4565.
4. Hajarizadeh B, Grebely J, Dore GJ,. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10 (9): 553-562.
5. Kershenobich D, Razavi HA, Cooper CL, et al,. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int 2011; 31 (Suppl 2): 4-17.
6. Huang H, Sun F, Owen DM, et al,. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA 2007; 104 (14): 5848-5853.
7. Chang KS, Jiang J, Cai Z, Luo G,. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol 2007; 81 (24): 13783-13793.
8. Andre P, Komurian-Pradel F, Deforges S, et al,. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76 (14): 6919-6928.
9. Popescu CI, Dubuisson J,. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol Cell 2010; 102 (1): 63-74.
10. Germi R, Crance JM, Garin D, et al,. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 2002; 68 (2): 206-215.
11. Molina S, Castet V, Fournier-Wirth C, et al,. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 2007; 46 (3): 411-419.
12. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX,. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96 (22): 12766-12771.
13. Sabile A, Perlemuter G, Bono F, et al,. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology 1999; 30 (4): 1064-1076.
14. Grove J, Nielsen S, Zhong J, et al,. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 2008; 82 (24): 12020-12029.
15. Prentoe J, Jensen TB, Meuleman P, et al,. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol 2011; 85 (5): 2224-2234.
16. Bassendine MF, Sheridan DA, Felmlee DJ, Bridge SH, Toms GL, Neely RD,. HCV and the hepatic lipid pathway as a potential treatment target. J Hepatol 2011; 55 (6): 1428-1440.
17. Zhao Y, Ren Y, Zhang X, et al,. Ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape. J Immunol 2014; 193 (2): 783-796.
18. Keck ZY, Xia J, Wang Y, et al,. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog 2012; 8 (4): e1002653.
19. Tao W, Xu C, Ding Q, et al,. A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles. Virology 2009; 395 (1): 67-76.
20. Lee JY, Acosta EG, Stoeck IK, et al,. Apolipoprotein E likely contributes to a maturation step of infecti-ous hepatitis C virus particles and interacts with viral envelope glycoproteins. J Virol 2014; 88 (21): 12422-12437.
21. Shimizu Y, Hishiki T, Sugiyama K, et al,. Lipoprotein lipase and hepatic triglyceride lipase reduce the infectivity of hepatitis C virus (HCV) through their catalytic activities on HCV-associated lipoproteins. Virology 2010; 407 (1): 152-159.
22. Bartosch B, Verney G, Dreux M, et al,. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005; 79 (13): 8217-8229.
23. Lavillette D, Morice Y, Germanidis G, et al,. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005; 79 (10): 6023-6034.
24. Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N,. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 2005; 280 (9): 7793-7799.